Topic: multiple sclerosis
Teva's Copaxone is losing ground to generic competition—and the company's newer drugs aren’t taking off fast enough to make up for the loss.
After a strong fourth quarter, Sanofi expects further growth in 2019.
Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.
After releasing strong earnings, Biogen's executives did their best to reassure analysts that the success of the pipeline won't rely solely on Alzheimer's.
As the appeal process could take years, the uncertainty introduces a new overhang at Perrigo, said one analyst.
Leerink analysts predict a doubling of competitive intensity in 15 disease areas by 2023, putting a dozen companies at risk.
Sanofi’s Lemtrada is already struggling in a tough multiple sclerosis field, and a new FDA safety warning isn’t going to help matters.
Merck KGaA's EMD Serono wants to know what’s on the minds of multiple sclerosis patients and their loved ones.
Concerns about discounting on Teva's migraine drug Ajovy are high as the company's generics unit and MS blockbuster falter.
Biogen outperformed this quarter, but analysts still worry about competition for Spinraza and an Alzheimer's candidate that hasn't yet proved out.